> top > docs > PubMed:7691188 > annotations

PubMed:7691188 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 299-318 gene:100 denotes adenosine deaminase
T1 408-412 disease:C0085110 denotes SCID
T2 1708-1711 gene:100 denotes ADA
T3 1770-1774 disease:C0085110 denotes SCID
T4 1764-1767 gene:100 denotes ADA
T5 1770-1774 disease:C0085110 denotes SCID
R1 T0 T1 associated_with adenosine deaminase,SCID
R2 T2 T3 associated_with ADA,SCID
R3 T4 T5 associated_with ADA,SCID

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
7691188-0#104#108#gene947 104-108 gene947 denotes CD34
7691188-0#177#180#gene100 177-180 gene100 denotes ADA
7691188-0#13#53#diseaseC0085110 13-53 diseaseC0085110 denotes severe combined immunodeficiency disease
7691188-0#55#59#diseaseC0085110 55-59 diseaseC0085110 denotes SCID
7691188-0#13#53#diseaseC0085110 13-53 diseaseC0085110 denotes severe combined immunodeficiency disease
7691188-0#55#59#diseaseC0085110 55-59 diseaseC0085110 denotes SCID
104#108#gene94713#53#diseaseC0085110 7691188-0#104#108#gene947 7691188-0#13#53#diseaseC0085110 associated_with CD34,severe combined immunodeficiency disease
104#108#gene94755#59#diseaseC0085110 7691188-0#104#108#gene947 7691188-0#55#59#diseaseC0085110 associated_with CD34,SCID
104#108#gene94713#53#diseaseC0085110 7691188-0#104#108#gene947 7691188-0#13#53#diseaseC0085110 associated_with CD34,severe combined immunodeficiency disease
104#108#gene94755#59#diseaseC0085110 7691188-0#104#108#gene947 7691188-0#55#59#diseaseC0085110 associated_with CD34,SCID
177#180#gene10013#53#diseaseC0085110 7691188-0#177#180#gene100 7691188-0#13#53#diseaseC0085110 associated_with ADA,severe combined immunodeficiency disease
177#180#gene10055#59#diseaseC0085110 7691188-0#177#180#gene100 7691188-0#55#59#diseaseC0085110 associated_with ADA,SCID
177#180#gene10013#53#diseaseC0085110 7691188-0#177#180#gene100 7691188-0#13#53#diseaseC0085110 associated_with ADA,severe combined immunodeficiency disease
177#180#gene10055#59#diseaseC0085110 7691188-0#177#180#gene100 7691188-0#55#59#diseaseC0085110 associated_with ADA,SCID

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 141-146 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T2 1505-1510 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T3 1802-1807 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T4 1479-1490 http://purl.obolibrary.org/obo/UBERON_0002371 denotes bone marrow
PD-UBERON-AE-B_T5 1563-1581 http://purl.obolibrary.org/obo/UBERON_0002390 denotes hematopoietic stem

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1770 104-108 gene:947 denotes CD34
T1771 68-98 disease:C0268124 denotes adenosine deaminase deficiency
T1772 177-180 gene:100 denotes ADA
R1 T1770 T1771 associated_with CD34,adenosine deaminase deficiency
R2 T1770 T1771 associated_with CD34,adenosine deaminase deficiency
R3 T1772 T1771 associated_with ADA,adenosine deaminase deficiency
R4 T1772 T1771 associated_with ADA,adenosine deaminase deficiency

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-186 Sentence denotes Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene.
TextSentencer_T2 187-262 Sentence denotes Amendment to clinical research project, Project 90-C-195, January 10, 1992.
TextSentencer_T3 263-530 Sentence denotes Significant increases in lymphocyte adenosine deaminase activity, T cell numbers and immune function have been achieved in the two children with SCID thus far treated with autologous T cells genetically-corrected by retroviral-mediated insertion of a normal ADA gene.
TextSentencer_T4 531-811 Sentence denotes Although the data obtained to date demonstrate that the use of ADA gene corrected peripheral T cells appears to be an effective treatment for ADA(-)SCID, it is theoretically preferable to try to develop a treatment for these children that will result in stem cell gene correction.
TextSentencer_T5 812-1102 Sentence denotes The genetic correction of T cell progenitors with long-term immune reconstituting ability would be more desirable because repeated infusions of genetically altered cells should not be necessary and the generation of a more complete repertoire of T cell specificities might also be possible.
TextSentencer_T6 1103-1225 Sentence denotes Furthermore, the present treatment protocol involves indefinite continuation of enzyme replacement treatment with PEG-ADA.
TextSentencer_T7 1226-1428 Sentence denotes The demonstration of ADA gene expression in the progeny of transduced stem cells may simplify the decision concerning cessation of this very costly enzyme treatment (approximately $250,000/yr./patient).
TextSentencer_T8 1429-1642 Sentence denotes Recent evidence suggests that a small fraction of bone marrow or peripheral blood mononuclear cells bearing the CD34 antigen contains hematopoietic stem cells with both lymphoid and myeloid reconstituting ability.
TextSentencer_T9 1643-1914 Sentence denotes We propose in this amendment to supplement the infusion of human ADA gene-transduced autologous T cells in children with ADA(-)SCID with autologous peripheral blood CD34+ cells transduced with a second, readily distinguishable ADA vector.(ABSTRACT TRUNCATED AT 250 WORDS)
T1 0-186 Sentence denotes Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene.
T2 187-262 Sentence denotes Amendment to clinical research project, Project 90-C-195, January 10, 1992.
T3 263-530 Sentence denotes Significant increases in lymphocyte adenosine deaminase activity, T cell numbers and immune function have been achieved in the two children with SCID thus far treated with autologous T cells genetically-corrected by retroviral-mediated insertion of a normal ADA gene.
T4 531-811 Sentence denotes Although the data obtained to date demonstrate that the use of ADA gene corrected peripheral T cells appears to be an effective treatment for ADA(-)SCID, it is theoretically preferable to try to develop a treatment for these children that will result in stem cell gene correction.
T5 812-1102 Sentence denotes The genetic correction of T cell progenitors with long-term immune reconstituting ability would be more desirable because repeated infusions of genetically altered cells should not be necessary and the generation of a more complete repertoire of T cell specificities might also be possible.
T6 1103-1225 Sentence denotes Furthermore, the present treatment protocol involves indefinite continuation of enzyme replacement treatment with PEG-ADA.
T7 1226-1428 Sentence denotes The demonstration of ADA gene expression in the progeny of transduced stem cells may simplify the decision concerning cessation of this very costly enzyme treatment (approximately $250,000/yr./patient).
T8 1429-1642 Sentence denotes Recent evidence suggests that a small fraction of bone marrow or peripheral blood mononuclear cells bearing the CD34 antigen contains hematopoietic stem cells with both lymphoid and myeloid reconstituting ability.
T9 1643-1914 Sentence denotes We propose in this amendment to supplement the infusion of human ADA gene-transduced autologous T cells in children with ADA(-)SCID with autologous peripheral blood CD34+ cells transduced with a second, readily distinguishable ADA vector.(ABSTRACT TRUNCATED AT 250 WORDS)

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 141-146 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T2 1505-1510 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T3 1802-1807 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T4 1479-1490 http://purl.obolibrary.org/obo/UBERON_0002371 denotes bone marrow